Tuesday, August 2, 2016

WEBINAR: Is adaptive design the future of clinical trials?

In recent years, the development of novel compounds has slowed down, due in part to rapidly escalating costs and the increased complexity to get approval from Health Authorities. 

To reverse this trend, the Food and Drug Administration released the critical path initiative in 2004 and the critical path opportunity list in 2006. There is clearly a need for advancing innovative trial designs, and adaptive clinical trials is one of the solutions. Coupling adaptive designs with other initiatives for improving clinical trial quality and efficiency shows strong promise in addressing the challenge of improving R&D performance. 

Isabelle Naëije, Clinical Trial Head at Novartis, will be leading a free webinar on the benefits and limitations of adaptive design based on her own extensive experience. She will begin with a definition of what adaptive design actually means, before going on to describe the different types, their benefits and the concerns around them. 
  • When? Wednesday 10th August 2016 2pm - 3pm BST
  • Who? Isabelle Naëije is currently based in Basel, Switzerland. She is the Clinical Trial Head in charge of a Phase I-II study in the field of Renal Cell Carcinoma sponsored by Novartis, in collaboration with Merck. Before taking this role, she worked for 5 years at Actelion Pharmaceuticals Ltd, Switzerland as Project Manager in the Clinical Pharmacology department.

No comments: